Satellos Bioscience Inc (MSLE)

02:37 AM

Cantor Fitzgerald Initiates Coverage on Satellos Bioscience (NASDAQ:MSLE) - Defense World

02:37 AM

Mar 12, 2026

(MSCL) Comprehensive Trading Strategy Report (MSCL:CA) - Stock Traders Daily

Mar 12, 2026

Mar 11, 2026

The Canadian biotech stock will beat the market, analyst says - Cantech Letter

Mar 11, 2026

Mar 10, 2026

Satellos Bioscience Inc. - Mena FN

Mar 10, 2026

Mar 10, 2026

Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference - Bitget

Mar 10, 2026

Mar 10, 2026

Satellos Bioscience Unveils Positive Interim SAT-3247 Data in Duchenne Muscular Dystrophy at MDA 2026 - TipRanks

Mar 10, 2026

Mar 09, 2026

(MSCL) Advanced Equity Analysis (MSCL:CA) - Stock Traders Daily

Mar 09, 2026

Mar 07, 2026

Satellos prices $50M public offering - MSN

Mar 07, 2026

Mar 06, 2026

(MSCL) Technical Analysis and Trading Signals (MSCL:CA) - Stock Traders Daily

Mar 06, 2026

Mar 06, 2026

Satellos Bioscience Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView

Mar 06, 2026

Mar 04, 2026

(MSCL) Trading Performance and Risk Management (MSCL:CA)Stock Traders Daily Canada - Stock Traders Daily

Mar 04, 2026

Feb 27, 2026

MSCLFSatellos Bioscience Inc Latest Stock News & Market Updates - Stock Titan

Feb 27, 2026

Feb 26, 2026

(MSCL) Strategic Market Analysis (MSCL:CA) - Stock Traders Daily

Feb 26, 2026

Feb 26, 2026

Satellos Bioscience (MSLE) Stock Analysis Report | Financials & Insights - Benzinga España

Feb 26, 2026

Feb 24, 2026

Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference - BioSpace

Feb 24, 2026

Feb 24, 2026

Stocks in play: Satellos Bioscience Inc. - The Globe and Mail

Feb 24, 2026

Feb 24, 2026

Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association - PharmiWeb.com

Feb 24, 2026

Feb 24, 2026

Satellos to Showcase New SAT-3247 DMD and FSHD Data at 2026 MDA Conference - TipRanks

Feb 24, 2026

Feb 24, 2026

Satellos (Nasdaq: MSLE) plans SAT-3247 data at 2026 MDA meeting - Stock Titan

Feb 24, 2026

Feb 23, 2026

(MSCL) Market Insights and Trading Signals (MSCL:CA) - Stock Traders Daily

Feb 23, 2026

Feb 19, 2026

Satellos Bioscience to Court Investors as Phase 2 DMD Program Advances - TipRanks

Feb 19, 2026

Feb 18, 2026

Satellos to Participate in Upcoming Investor Conferences - Investing News Network

Feb 18, 2026

Feb 18, 2026

Satellos to Host February 24 Virtual KOL Event Showcasing SAT-3247 in Duchenne Muscular Dystrophy - TipRanks

Feb 18, 2026

Feb 18, 2026

Satellos (NASDAQ: MSLE) sets virtual KOL event on SAT-3247 DMD program - Stock Titan

Feb 18, 2026

Feb 18, 2026

Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy - PharmiWeb.com

Feb 18, 2026

Feb 18, 2026

Inside Satellos’ experimental DMD pill at live online event - Stock Titan

Feb 18, 2026

Feb 17, 2026

(MSCL) Equity Trading Insights (MSCL:CA) - Stock Traders Daily

Feb 17, 2026

Feb 17, 2026

US$57.2M raise and Nasdaq Global Market listing for Satellos Bioscience (NASDAQ: MSLE) - Stock Titan

Feb 17, 2026

Feb 17, 2026

1st boys dosed in Phase 2 trial of oral DMD treatment SAT-3247 - Muscular Dystrophy News

Feb 17, 2026

Feb 17, 2026

Satellos to Highlight Duchenne Drug Program at Series of Investor Conferences - TipRanks

Feb 17, 2026

Feb 14, 2026

(MSCL) Dynamic Trading Report (MSCL:CA) - Stock Traders Daily

Feb 14, 2026

Feb 13, 2026

United StatesMintz Advises Satellos Bioscience In Its US$57.2 Million Initial US Public Offering - Mondaq

Feb 13, 2026

Feb 13, 2026

Satellos Bioscience (NASDAQ:MSLE) Upgraded at Zacks Research - Defense World

Feb 13, 2026

Feb 12, 2026

Total liabilities of Satellos Bioscience Inc. – BOATS:MSLE - TradingView

Feb 12, 2026

Feb 12, 2026

Satellos Bioscience (MSLE) Stock Chart and Price History 2026 - MarketBeat

Feb 12, 2026

Feb 12, 2026

Satellos Bioscience (MSLE) Stock Trends and Sentiment 2026 - MarketBeat

Feb 12, 2026

Feb 12, 2026

Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy - Investing News Network

Feb 12, 2026

Feb 12, 2026

Satellos Bioscience Doses First Patient in Phase 2 Pediatric Duchenne Study of SAT-3247 - TipRanks

Feb 12, 2026

Feb 12, 2026

Free cash flow per share of Satellos Bioscience Inc. – BOATS:MSLE - TradingView

Feb 12, 2026

Feb 11, 2026

Satellos Bioscience Completes US$57.2 Million Cross-Border Public Offering and Nasdaq Listing - Global Legal Chronicle

Feb 11, 2026

Feb 11, 2026

This Canadian biotech stock is undervalued, analyst says - Cantech Letter

Feb 11, 2026

Feb 11, 2026

Satellos price target raised to $40 from $5 at Oppenheimer - Yahoo Finance

Feb 11, 2026

Feb 10, 2026

Satellos Closes US$57.2 Million Public Offering in Canada and the United States - 富途牛牛

Feb 10, 2026

Feb 10, 2026

Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - PharmiWeb.com

Feb 10, 2026

Feb 10, 2026

Satellos Bioscience to Highlight Muscle-Regeneration Platform at Guggenheim Biotech Summit 2026 - TipRanks

Feb 10, 2026

Feb 10, 2026

Mintz Advises Satellos Bioscience in its US$57.2 Million Initial US Public Offering - Mintz

Feb 10, 2026

Feb 10, 2026

Satellos Bioscience Raises US$57.2 Million in Cross-Border Equity Offering to Advance Muscle Disease Pipeline - TipRanks

Feb 10, 2026

Feb 10, 2026

Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares - BioSpace

Feb 10, 2026

Feb 10, 2026

Latham Advises on Satellos’ US$50 Million Initial US Offering - Legal Desire Media and Insights

Feb 10, 2026